Earnings Call Summary | Revvity(RVTY.US) Q1 2024 Earnings Conference
Earnings Call Summary | Revvity(RVTY.US) Q1 2024 Earnings Conference
The following is a summary of the Revvity, Inc. (RVTY) Q1 2024 Earnings Call Transcript:
以下是Revvity, Inc.（RVTY）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Revvity reported Q1 revenues of $650 million, a decrease of 3% in organic revenue.
The company's Q1 adjusted operating margins rose to 25.5%, above expectations.
Free cash flow amounted to $132 million, with the anticipation of continued positive trends and added cash flows from last year's divestitures.
Adjusted EPS for Q1 was at $0.98, above the median of their expectations.
Revvity报告称，第一季度收入为6.5亿美元，有机收入下降了3％。
该公司第一季度调整后的营业利润率升至25.5％，高于预期。
自由现金流达1.32亿美元，预计去年的资产剥离将带来持续的积极趋势并增加现金流。
第一季度调整后的每股收益为0.98美元，高于预期的中位数。
Business Progress:
业务进展：
The company saw low-double-digit growth in its largest diagnostics segment, the immunodiagnostics franchise.
New product launches have begun in Revvity's Signals Software business, contributing to high single-digit growth in Q1.
The company successfully integrated several acquisitions, which it believes will bolster internal collaboration and enhance key initiatives.
Plans to streamline the company are in motion, focusing on footprint consolidation, logistical optimization, vendor consolidation, and in-sourcing opportunities.
The software business outperformed expectations with new product launches, anticipating high-single-digit to low-double-digit annual growth.
Revvity expects low-single-digit growth in its core reagents business for Q2, with mid-single-digit growth foreseen for the full year.
Strong growth in the newborn business and immunodiagnostics, outside of China, is expected to continue.
The company is taking steps to support pharma/biotech customers as they realign their portfolios, moving efficiently from discovery to development.
A new automated tuberculosis testing system was presented, significantly reducing hands-on time and technician touch points, providing a considerable competitive edge.
该公司最大的诊断领域——免疫诊断专营权——实现了低两位数的增长。
Revvity的信号软件业务已开始推出新产品，为第一季度的高个位数增长做出了贡献。
该公司成功整合了几项收购，它认为这将加强内部合作并加强关键举措。
精简公司的计划正在进行中，重点是足迹整合、物流优化、供应商整合和内包机会。
软件业务在新产品的发布中表现超出预期，预计年增长将高个位数至低两位数。
Revvity预计，其核心试剂业务将在第二季度实现低个位数的增长，预计全年将实现中等个位数的增长。
预计中国以外的新生儿业务和免疫诊断业务将继续强劲增长。
该公司正在采取措施支持制药/生物技术客户调整其产品组合，高效地从发现转向开发。
提出了一种新的自动化结核病检测系统，显著减少了动手时间和技术人员的接触点，提供了相当大的竞争优势。
More details: Revvity IR
更多详情： 活力红外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。